Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia
Completed
The purpose of this study is to find out if the combination of bortezomib (Velcade), dexamethasone (Decadron) and rituximab (Rituxan) is effective in treating Waldenstrom's macroglobulinemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2016
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +1 locations
Conditions: Waldenstrom's Macroglobulinemia
Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma
Unknown
The purpose of this clinical research study is to evaluate the safety and effectiveness (good and bad effects) of a combination of three different drugs, pomalidomide, pegylated liposomal doxorubicin, and dexamethasone when used to treat relapsed (the disease came back) or refractory (the disease did not respond to past treatment) multiple myeloma. Different dosages (amount of study drug) of pomalidomide are first being tested to determine if there are any side effects or risks associated with c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/08/2016
Locations: Roy and Patricia Disney Family Cancer Center, Burbank, California +7 locations
Conditions: Multiple Myeloma
Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating childhood acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is comparing different combination chemotherapy regimens to see how well they work in treating children with acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 1 year and 9 years
Trial Updated:
02/19/2016
Locations: Phoenix Children's Hospital, Phoenix, Arizona +129 locations
Conditions: Leukemia
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radioactive substances such as strontium-89 may relieve bone pain associated with prostate cancer. It is not yet known whether chemotherapy is more effective with or without strontium-89 in treating bone metastases. PURPOSE: This randomized phase III trial is studying giving chemotherapy together with strontium-89 to see how well it works compared to chemotherapy alone in trea... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
02/19/2016
Locations: Northeast Georgia Medical Center, Gainesville, Georgia +39 locations
Conditions: Prostate Cancer
Blood and Marrow Transplant Clinical Research Network
Completed
The purpose of this network is to accelerate research in hematopoietic stem cell transplantation by comparing novel therapies to existing ones.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
02/17/2016
Locations: City of Hope National Medical Center, Duarte, California +15 locations
Conditions: Bone Marrow Transplantation, Blood Disease, Hematopoietic Stem Cell Transplantation, Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Graft vs Host Disease
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
Completed
RATIONALE: Antiemetic drugs, such as aprepitant, granisetron, and dexamethasone, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. PURPOSE: This clinical trial is studying how well giving aprepitant together with granisetron and dexamethasone works in preventing nausea and vomiting in patients receiving cyclophosphamide before undergoing an autologous stem cell transplant.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
02/12/2016
Locations: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan
Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction
Completed
The purpose of this study is to characterize the pharmacokinetics (blood levels) of trabectedin after administration to patients with advanced malignancies and hepatic (liver) dysfunction.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/12/2016
Locations: Not set, Scottsdale, Arizona +10 locations
Conditions: Neoplasm Metastases, Hepatic Insufficiency
SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma
Withdrawn
The purpose of this study is to determine if adding SOM230 LAR to bortezomib and dexamethasone is better than bortezomib and dexamethasone alone and if it should be investigated further.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2016
Locations: Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Multiple Myeloma in Relapse, Multiple Myeloma
Ph3 Safety/Efficacy Study of Rolapitant for the Prevention of CINV in Subjects Receiving Highly Emetogenic Chemotherapy
Completed
This is a Phase 3, multicenter, randomized, parallel-group, double-blind, active-controlled study of rolapitant in subjects receiving HEC. Rolapitant or placebo will be administered 1-2 hours prior to initiation of chemotherapy on Day 1 with granisetron and dexamethasone. Subjects will record all events of emesis and use of rescue medication for established nausea and/or vomiting, and will indicate the severity of nausea they experienced in each of the previous 24 hours in the Nausea and Vomitin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/02/2016
Locations: TESARO Inc, Waltham, Massachusetts
Conditions: Chemotherapy-induced Nausea and Vomiting
Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy
Completed
This is a Phase 3, multicenter, randomized, parallel-group, double-blind, active-controlled study of rolapitant in subjects receiving MEC. Rolapitant or placebo will be administered prior to the initiation of chemotherapy on Day 1 with granisetron and dexamethasone. Subjects will record all events of emesis and the use of rescue medication for established nausea and/or vomiting, and will indicate the severity of nausea they experienced in each of the previous 24 hours in the Nausea and Vomiting... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/02/2016
Locations: TESARO Inc, Waltham, Massachusetts
Conditions: Chemotherapy-induced Nausea and Vomiting
Calcitriol and Dexamethasone in Patients With Myelodysplastic Syndromes
Completed
This is a study to determine the response rate in patients with myelodysplastic syndromes treated with calcitriol and dexamethasone.
Gender:
ALL
Ages:
All
Trial Updated:
01/14/2016
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Myelodysplastic Syndromes
Single Oral Dose of Dexamethasone Versus Five Days of Prednisone in Adult Asthma
Completed
This study seeks to compare the effectiveness of a single dose of oral dexamethasone versus 5 days of oral prednisone in the treatment of mild to moderate asthma exacerbations to prevent relapse with an unscheduled return visit to a health care provider for additional asthma treatment within 14 days. The investigators hypothesize that the two treatments will be equally effective in relapse prevention.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
01/05/2016
Locations: Alameda County Medical Center, Oakland, California
Conditions: Asthma, Reactive Airway Disease